United States - English - NLM (National Library of Medicine)

jubilant cadista pharmaceuticals inc - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 5 mg - olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies (14.1)] .   when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)] . monotherapy — olanzapine orally disintegrating tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in th

United States - English - NLM (National Library of Medicine)

american regent, inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 10 mg in 2 ml - olanzapine for injection is indicated for the treatment of acute agitation associated with schizophrenia and bipolar i mania. efficacy was demonstrated in 3 short-term (24 hours of intramuscular treatment) placebo-controlled trials in agitated adult inpatients with: schizophrenia or bipolar i disorder (manic or mixed episodes) [see clinical studies (14.3)]. “psychomotor agitation” is defined in dsm-iv as “excessive motor activity associated with a feeling of inner tension.” patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation. - none with olanzapine monotherapy. - for specific information about the contraindications of lithium or valproate, refer to the contraindications section of the package inserts for these other products. pregnancy expos

United States - English - NLM (National Library of Medicine)

proficient rx lp - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 5 mg - oral olanzapine is indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13-17), efficacy was established in one 6-week trial [see clinical studies (14.1)].  when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5, 5.6)]. monotherapy — oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with manic or mix

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 10 mg in 2 ml - olanzapine for injection  is indicated for the treatment of acute agitation associated with schizophrenia and bipolar i mania. efficacy was demonstrated in 3 short-term (24 hours of im treatment) placebo-controlled trials in agitated adult inpatients with: schizophrenia or bipolar i disorder (manic or mixed episodes) [see   clinical studies ( ) 14.3 ]. “psychomotor agitation” is defined in dsm-iv as “excessive motor activity associated with a feeling of inner tension.” patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation. - none with olanzapine for injection monotherapy. - for specific information about the contraindications of lithium or valproate, refer to the contr

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 10 mg - oral olanzapine tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13-17), efficacy was established in one 6-week trial [see clinical studies ( 14.1)].  when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidema. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions ( 5.5)]. monotherapy — oral olanzapine tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 10 mg in 2 ml - olanzapine for injection is indicated for the treatment of acute agitation associated with schizophrenia and bipolar i mania. efficacy was demonstrated in 3 short-term (24 hours of im treatment) placebo-controlled trials in agitated adult inpatients with: schizophrenia or bipolar i disorder (manic or mixed episodes) [see ]. clinical studies ( 14.3) “psychomotor agitation” is defined in dsm-iv as “excessive motor activity associated with a feeling of inner tension.” patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation. - none with olanzapine monotherapy. - for specific information about the contraindications of lithium or valproate, refer to the contraindications section of the package inserts for these othe

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - olanzapine 10mg - film coated tablet - 10 mg - active: olanzapine 10mg excipient: hyprolose hypromellose lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide - olanzapine is indicated for the treatment of schizophrenia and related psychoses.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - olanzapine 15mg - film coated tablet - 15 mg - active: olanzapine 15mg excipient: hyprolose hypromellose indigo carmine lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide - olanzapine is indicated for the treatment of schizophrenia and related psychoses.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - olanzapine 2.5mg - film coated tablet - 2.5 mg - active: olanzapine 2.5mg excipient: hyprolose hypromellose lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide - olanzapine is indicated for the treatment of schizophrenia and related psychoses.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - olanzapine 20mg - film coated tablet - 20 mg - active: olanzapine 20mg excipient: hyprolose hypromellose iron oxide red iron oxide yellow lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide - olanzapine is indicated for the treatment of schizophrenia and related psychoses.